Medpedia

• Sarcoma

DISEASE CHARACTERISTICS:
-  Newly diagnosed or recurrent Ewing's sarcoma
-  Availability of the following specimens:
-  Paraffin-embedded block or 20 unstained slides and 1-3 thick (50 micron)
sections from initial biopsy
-  Pretreatment serum and whole blood
-  Concurrent therapy is not required
PATIENT CHARACTERISTICS:
Age
-  50 and under
Performance status
-  Not specified
Life expectancy
-  Not specified
Hematopoietic
-  Not specified
Hepatic
-  Not specified
Renal
-  Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy
-  Not specified
Chemotherapy
-  Not specified
Endocrine therapy
-  Not specified
Radiotherapy
-  Not specified
Surgery
-  Not specified

OBJECTIVES:

-  Determine the prognostic significance of chromosomal translocation subtype in patients
with Ewing's sarcoma.

-  Determine the prognostic significance of minimal residual disease detection in bone
marrow of these patients, using reverse transcriptase-polymerase chain reaction
determination of EWS-ETS fusion genes.

-  Determine whether serum levels of IGF1 and IGFBP3 are of significance to outcome of
these patients.

-  Establish clinical proteomics for investigating altered signaling molecules in the
pathogenesis of Ewing's sarcoma.

OUTLINE: This is a multicenter study.

Patients undergo various specimen collections, including bone marrow aspirate,
paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens.
These specimens are collected before, during, and after any chemotherapy regimens, during
follow-up, and at time of recurrence. Translocation studies are performed on specimens to
identify fusion genes, specifically EWS-ETS. Serum IGF1 and IFGBP3 levels are determined.
Bone marrow is assessed for minimal residual disease using reverse-transcriptase polymerase
chain reaction.

PROJECTED ACCRUAL: A total of 470 patients will be accrued for this study within 4 years.

• : chromosomal translocation analysis
• : cytogenetic analysis
• : mutation analysis
• : proteomic profiling
• : reverse transcriptase-polymerase chain reaction

• Daniel C. West, MD
  Study Chair, University of California, Davis

• Swiss Pediatric Oncology Group Geneva
  Geneva, 1205, Switzerland
  Active, not recruiting
• Swiss Pediatric Oncology Group Bern
  Bern, 3010, Switzerland
  Active, not recruiting
• San Jorge Children's Hospital
  Santurce, 00912, Puerto Rico
  Active, not recruiting
• Starship Children's Health
  Auckland, 1, New Zealand
  Active, not recruiting
• Centre Hospitalier Universitaire de Quebec
  Quebec, G1V 4G2, Canada
  Active, not recruiting
• Saskatoon Cancer Centre at the University of Saskatchewan
  Saskatoon, Saskatchewan, S7N 4H4, Canada
  Active, not recruiting
• Allan Blair Cancer Centre at Pasqua Hospital
  Regina, Saskatchewan, S4T 7T1, Canada
  Active, not recruiting
• Montreal Children's Hospital at McGill University Health Center
  Montreal, Quebec, H3H 1P3, Canada
  Active, not recruiting
• Hopital Sainte Justine
  Montreal, Quebec, H3T 1C5, Canada
  Active, not recruiting
• Hospital for Sick Children
  Toronto, Ontario, M5G 1X8, Canada
  Active, not recruiting
• Children's Hospital of Eastern Ontario
  Ottawa, Ontario, K1H 8L1, Canada
  Active, not recruiting
• Cancer Centre of Southeastern Ontario at Kingston General Hospital
  Kingston, Ontario, K7L 3N6, Canada
  Active, not recruiting

• Children's Oncology Group
  Lead Sponsor
• United States: Federal Government

• Clinical trial summary from the National Cancer Institute's PDQ® database
  http://cancer.gov/clinicaltrials/COG-AEWS02B1